Aflibercept versus ranibizumab for diabetic macular edema: A meta-analysis

CONCLUSION: This study found that there was no difference in BCVA, CMT or adverse reactions between AFL and RAN at 6 and 12 months of follow-up, but AFL needed fewer IVIs than RAN.PMID:37226427 | DOI:10.1177/11206721231178658

Source: European Journal of Ophthalmology - May 25, 2023 Category: Opthalmology Authors: Haiyan Chen Xuehui Shi Wang Zhang Qianqian Han Source Type: research